Format

Send to

Choose Destination
BMC Cancer. 2016 Feb 27;16:167. doi: 10.1186/s12885-016-2208-2.

Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.

Author information

1
Division of Hematology & Medical Oncology, Mayo Clinic Cancer Center, 13400 E. Shea Blvd, Scottsdale, AZ, 85259, USA. mesa.ruben@mayo.edu.
2
St. Agnes Hospital, 900 S Caton Ave, Baltimore, MD, 21229, USA. cmiller@stagnes.org.
3
Weill Cornell Medical College, 525 E 68Th St Starr 341, New York, NY, 10065, USA. mthyne@gmail.com.
4
University of Pennsylvania, Abramson Cancer Center, Perelman Center for Advanced Medicine, West Pavilion, 2nd Floor, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA. James.Mangan@uphs.upenn.edu.
5
Cancer Support Community, 165 W46th Street Suite 1002, New York, NY, 10036, USA. sara@cancersupportcommunity.org.
6
Allegheny Health Network, 4815 Liberty, Mellon Suite 340, Pittsburgh, PA, 15224, USA. sfazal@wpahs.org.
7
Yale School of Public Health, Laboratory of Epidemiology and Public Health, 60 College Street, Suite 406, New Haven, CT, 06510, USA. xiaomei.ma@yale.edu.
8
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. North, LF-210, Seattle, WA, 98109, USA. wwilson@fhcrc.org.
9
Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE, 19803, USA. dparanagama@incyte.com.
10
Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE, 19803, USA. ddubinski@incyte.com.
11
ICF International, 530 Gaither Road, Suite 500, Rockville, MD, 20850, USA. john.boyle@icfi.com.
12
Icahn School of Medicine at Mount Sinai, Ruttenberg Treatment Center, 1470 Madison Avenue, 3rd Floor, New York, NY, 10029, USA. john.mascarenhas@mssm.edu.

Abstract

BACKGROUND:

The Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) negatively affect patient quality of life (QoL) and are associated with increased risk of mortality.

METHODS:

The MPN Landmark survey was conducted from May to July 2014 in patients with MF, PV, or ET under active management in the United States. The survey assessed respondent perceptions of disease burden and treatment management and included questions on overall disease burden, QoL, activities of daily living, and work productivity. Outcomes were further analyzed by calculated (ie, not respondent-reported) prognostic risk score and symptom severity quartile.

RESULTS:

The survey was completed by 813 respondents (MF, n = 207; PV, n = 380; ET, n = 226). The median respondent age in each of the 3 MPN subtypes ranged from 62 to 66 years; median disease duration was 4 to 7 years. Many respondents reported that they had experienced MPN-related symptoms ≥1 year before diagnosis (MF, 49 %; PV, 61 %; ET, 58 %). Respondents also reported that MPN-related symptoms reduced their QoL, including respondents with low prognostic risk scores (MF, 67 %; PV, 62 %; ET, 57 %) and low symptom severity (MF, 51 %; PV, 33 %; ET, 15 %). Many respondents, including those with a low prognostic risk score, reported that their MPN had caused them to cancel planned activities or call in sick to work at least once in the preceding 30 days (cancel planned activities: MF, 56 %; PV, 35 %; ET, 35 %; call in sick: MF, 40 %; PV, 21 %; ET, 23 %).

CONCLUSIONS:

These findings of the MPN Landmark survey support previous research about the symptom burden experienced by patients with MPNs and are the first to detail the challenges that patients with MPNs experience related to reductions in activities of daily living and work productivity.

PMID:
26922064
PMCID:
PMC4769833
DOI:
10.1186/s12885-016-2208-2
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center